{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Aromatase+Inhibitors+%28AIs%29", "query": { "intervention": "Aromatase Inhibitors (AIs)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 13, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Aromatase+Inhibitors+%28AIs%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-01T12:14:45.963Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05768139", "title": "First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer", "Solid Tumors, Adult" ], "interventions": [ { "name": "STX-478", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Ribociclib", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Anastrozole", "type": "DRUG" }, { "name": "Exemestane", "type": "DRUG" }, { "name": "Tamoxifen", "type": "DRUG" }, { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Imlunestrant", "type": "DRUG" }, { "name": "Metformin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 880, "start_date": "2023-04-17", "completion_date": "2030-07", "has_results": false, "last_update_posted_date": "2026-07-07", "last_synced_at": "2026-10-01T12:14:45.963Z", "location_count": 28, "location_summary": "Los Angeles, California • San Francisco, California • Aurora, Colorado + 22 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Lake Mary", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05768139" }, { "nct_id": "NCT01603303", "title": "Preventing Sexual Dysfunction With Aromatase Inhibitors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Questionnaires", "type": "BEHAVIORAL" }, { "name": "Education Materials", "type": "OTHER" }, { "name": "Luvena", "type": "OTHER" }, { "name": "Hyalo-Gyn", "type": "OTHER" }, { "name": "Vaginal Lubricant", "type": "OTHER" }, { "name": "Interactive Internet-Based Website", "type": "BEHAVIORAL" }, { "name": "Telephone Counseling.", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 187, "start_date": "2012-12-05", "completion_date": "2017-08-11", "has_results": false, "last_update_posted_date": "2017-08-18", "last_synced_at": "2026-10-01T12:14:45.963Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01603303" }, { "nct_id": "NCT03144037", "title": "Adherence of Hispanic / Latina Breast Cancer - Patients to Adjuvant Aromatase Inhibitors", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Breast Cancer" ], "interventions": [], "intervention_types": [], "sponsor": "Texas Tech University Health Sciences Center, El Paso", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 152, "start_date": "2017-04-26", "completion_date": "2021-03-19", "has_results": false, "last_update_posted_date": "2021-03-29", "last_synced_at": "2026-10-01T12:14:45.963Z", "location_count": 1, "location_summary": "El Paso, Texas", "locations": [ { "city": "El Paso", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03144037" }, { "nct_id": "NCT02095184", "title": "GCC 1366: Anti-Proliferative Response to NeoAdjuvant AIs in Overweight and Obese Patients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Anastrozole", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Maryland, Baltimore", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 42, "start_date": "2015-05-25", "completion_date": "2024-08-02", "has_results": true, "last_update_posted_date": "2026-04-15", "last_synced_at": "2026-10-01T12:14:45.963Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02095184" }, { "nct_id": "NCT05573126", "title": "Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hormone Receptor-positive Breast Cancer", "Hormone Receptor Positive HER-2 Negative Breast Cancer", "Metastatic Breast Cancer" ], "interventions": [ { "name": "EP0062", "type": "DRUG" }, { "name": "Elacestrant", "type": "DRUG" }, { "name": "Everolimus", "type": "DRUG" }, { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Exemestane", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ellipses Pharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 95, "start_date": "2023-01-11", "completion_date": "2028-02", "has_results": false, "last_update_posted_date": "2026-06-22", "last_synced_at": "2026-10-01T12:14:45.963Z", "location_count": 7, "location_summary": "New Haven, Connecticut • Tampa, Florida • Boston, Massachusetts + 4 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Tampa", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT05573126" }, { "nct_id": "NCT02213042", "title": "Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neoplasms, Breast" ], "interventions": [ { "name": "Lapatinib", "type": "DRUG" }, { "name": "Trastuzumab", "type": "BIOLOGICAL" }, { "name": "Aromatase Inhibitors (AIs)", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 42, "start_date": "2014-10-24", "completion_date": "2020-06-04", "has_results": true, "last_update_posted_date": "2021-10-13", "last_synced_at": "2026-10-01T12:14:45.963Z", "location_count": 3, "location_summary": "Mobile, Alabama • Boston, Massachusetts • Houston, Texas", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02213042" }, { "nct_id": "NCT04869943", "title": "Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "Enobosarm", "type": "DRUG" }, { "name": "Exemestane", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Veru Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 52, "start_date": "2021-10-12", "completion_date": "2024-01-09", "has_results": false, "last_update_posted_date": "2024-01-26", "last_synced_at": "2026-10-01T12:14:45.963Z", "location_count": 34, "location_summary": "Chandler, Arizona • Gilbert, Arizona • Glendale, California + 29 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Glendale", "state": "California" }, { "city": "Greenbrae", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04869943" }, { "nct_id": "NCT01074320", "title": "Measuring Musculoskeletal Symptoms in Patients Receiving Aromatase Inhibitors", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Other", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "HealthPartners Institute", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 150, "start_date": "2010-02", "completion_date": "2015-08", "has_results": false, "last_update_posted_date": "2015-12-16", "last_synced_at": "2026-10-01T12:14:45.963Z", "location_count": 2, "location_summary": "Robbinsdale, Minnesota • Saint Louis Park, Minnesota", "locations": [ { "city": "Robbinsdale", "state": "Minnesota" }, { "city": "Saint Louis Park", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01074320" }, { "nct_id": "NCT02874222", "title": "A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "surveys completed by subject", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "United States Naval Medical Center, San Diego", "sponsor_class": "FED", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "FEMALE", "summary": "18 Years to 60 Years · Female only" }, "enrollment_count": 13, "start_date": "2015-05", "completion_date": "2024-05-01", "has_results": false, "last_update_posted_date": "2024-06-06", "last_synced_at": "2026-10-01T12:14:45.963Z", "location_count": 1, "location_summary": "San Diego, California", "locations": [ { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02874222" }, { "nct_id": "NCT00365599", "title": "Phase II Trial of SAHA & Tamoxifen for Patients With Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "suberoylanilide hydroxamic acid (SAHA, Vorinostat)", "type": "DRUG" }, { "name": "tamoxifen citrate (Tamoxifen)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 43, "start_date": "2006-02", "completion_date": "2012-08", "has_results": true, "last_update_posted_date": "2014-11-21", "last_synced_at": "2026-10-01T12:14:45.963Z", "location_count": 8, "location_summary": "San Francisco, California • Boynton Beach, Florida • Orlando, Florida + 5 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Boynton Beach", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Port Charlotte", "state": "Florida" }, { "city": "Stuart", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00365599" } ] }